Why New Patients Compare These Leading Treatments
Is Mounjaro Better Than Wegovy for First-Time Users?
When considering whether Mounjaro is better than Wegovy for your starter dose, understanding the fundamental differences helps inform your decision. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, whilst Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors. Both begin with carefully designed starter doses—Wegovy at 0.25mg weekly and Mounjaro at 2.5mg weekly—to help your body adjust gradually. The starter phase is crucial for both medications, allowing patients to experience appetite changes whilst minimising potential side effects like nausea.
For new patients, the choice between these medications often comes down to individual response and practical considerations. Wegovy's 16-week dose escalation schedule is well-established, progressing from 0.25mg through to the 2.4mg maintenance dose. Mounjaro follows its own escalation pattern, moving from 2.5mg to its maximum 15mg dose. Your prescriber will consider your medical history, weight management goals, and any existing conditions to determine which starter approach suits you best.
Starter Dose Pricing and Value Comparison
Understanding the cost implications when asking "is Mounjaro better than Wegovy" requires examining both medications' pricing structures. Wegovy's 0.25mg starter dose costs £79.99 at EverydayMeds, with new customers applying discount code FIRST40 at checkout to reach this price. Our Intro Duo bundle provides both your 0.25mg starter and 0.5mg second-month doses for £169.99, offering convenient supply management for your first 8 weeks. This transparent pricing helps new patients budget for their weight management journey from the outset.
Both medications represent significant investments in your health, and the starter phase allows you to evaluate your response before committing to higher maintenance doses. Wegovy's pricing increases with dose strength, reaching £209.99 for the 2.4mg maintenance dose, whilst returning customers can apply code DOSE25 for ongoing savings. The starter phase pricing makes it accessible for patients to begin treatment, with the option to continue based on their individual response and tolerability during those crucial first four weeks.
Clinical Evidence: Is Mounjaro Better Than Wegovy in Trials?
When evaluating whether Mounjaro is better than Wegovy through clinical evidence, both medications have demonstrated significant efficacy in their respective trial programmes. Wegovy's evidence base includes the comprehensive STEP trial series, with STEP 1 showing participants achieved approximately 15% average weight loss at 68 weeks when combined with diet and exercise, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The recent SELECT trial also demonstrated a 20% reduction in major cardiovascular events, adding important safety data for long-term use.
Mounjaro's SURMOUNT trials have shown impressive results for tirzepatide in weight management, though direct comparison between trial results isn't appropriate due to different study designs, participant populations, and endpoints. Both medications require prescription alongside a reduced-calorie diet and increased physical activity, and individual responses can vary significantly. Your prescriber will consider the available evidence alongside your personal medical profile to guide treatment selection.
How Wegovy Works for New Patients
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a hormone naturally produced in your intestines. This mechanism helps reduce appetite by acting on brain centres that control hunger and satiety, making you feel fuller after smaller meals and potentially reducing food cravings throughout the day. The 0.25mg starter dose introduces this mechanism gently, allowing your digestive system to adapt whilst beginning to experience appetite changes. As a prescription-only medicine, Wegovy requires clinical assessment to ensure it's appropriate for your individual circumstances. The weekly injection schedule using the FlexTouch pen provides consistent medication levels, supporting steady appetite regulation throughout your treatment journey.
Your EverydayMeds Ordering Process
Starting your weight management journey through EverydayMeds begins with our streamlined 3-minute online clinical assessment, designed to gather essential medical information safely and efficiently. Our qualified prescribers, operating under GPhC registration #9012878, review your assessment thoroughly—standard review takes 3 working days, with express 24-hour options available for urgent needs. Once approved, your Wegovy starter dose ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our pharmacy team ensures each order meets MHRA standards for prescription-only medicines, providing the quality assurance you expect. The entire process prioritises your safety whilst offering the convenience of home delivery, making it simple to begin treatment discreetly and professionally.
Storage Advantages and Practical Considerations
When considering practical aspects of whether Mounjaro is better than Wegovy, storage requirements present a clear differentiator for many patients. Wegovy maintains potency for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This extended stability makes Wegovy particularly suitable for patients who travel frequently or prefer flexible storage options during treatment. The FlexTouch pen design ensures accurate dosing throughout the 16-week escalation schedule, with clear markings to track your progression from the 0.25mg starter dose. Proper storage in your refrigerator at 2-8°C before first use maintains medication effectiveness, whilst the room temperature tolerance provides peace of mind during daily use and travel situations.
First-Month Expectations: Mounjaro vs Wegovy Starter Experience
The starter dose experience often influences whether patients feel Mounjaro is better than Wegovy for their individual needs. Wegovy's 0.25mg starting dose typically produces gradual appetite changes over the first 2-3 weeks, with some patients noticing reduced portion sizes or decreased snacking between meals. Common initial effects may include mild nausea, particularly in the first few days after injection, which usually subsides as your body adjusts to the medication. Managing these early effects through proper hydration, smaller meals, and taking injections at consistent times helps optimise your starter experience.
Both medications require patience during the starter phase, as significant weight changes typically become apparent after several weeks of treatment combined with dietary modifications. Your first month provides valuable insight into how your body responds to GLP-1 receptor activation, helping inform decisions about dose escalation timing and long-term treatment strategy. Regular monitoring during this period, including tracking appetite changes and any side effects, supports successful progression through the dose escalation schedule.
Making Your Decision: Expert Guidance Available
Determining whether Mounjaro is better than Wegovy ultimately depends on individual factors including your medical history, lifestyle requirements, and treatment goals. Both medications are available through EverydayMeds, and our clinical team can help you navigate this important decision based on current evidence and your personal circumstances. The starter dose phase provides an opportunity to evaluate your response before committing to longer-term treatment, with our prescribers available for ongoing support and guidance. New customers can begin with confidence using discount code FIRST40, whilst our comprehensive support ensures you receive expert guidance throughout your weight management journey. Contact our clinical team today to discuss which option might suit your needs best, and take the first step towards effective weight management with professional support. Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
